[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aspirin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aspirin":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,86,145,175,203,231,267,295,319],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100389856","phase-3-chronic-hypertension-and-acetyl-salicylic-acid-in-pregnancy-100389856",false,"NCT04356326","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a Multicenter Prospective Randomized Double-blind Placebo-controlled Trial.","CHASAP","Inclusion Criteria:\n\n* Pregnant patient between 10 and 19 weeks of gestation + 6 days\n* Chronic hypertension, whether treated or not, know before pregnancy or diagnosed before randomization\n* Singleton pregnancy\n* Signed the written informed consent\n* Affiliation to social security\n\nExclusion Criteria:\n\n* ---Medical history requiring anticoagulation (antiphospholipid syndrome, deep vein thromboembolic disease, pulmonary embolism, atherothrombosis, patient with mechanical heart valves),\n* Patient receiving aspirin for another indication outside pregnancy,\n* Patient with significant proteinuria (\\> 300mg\u002F24 hours or a proteinuria\u002Fcreatininuria ratio ≥ 30mg\u002Fmmol),\n* Active bleeding,\n* History of severe PE with delivery \\\u003C 34 weeks of gestation,\n* Hypersensitivity to salicylates such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs),\n* Platelet count lower than 100,000 cells\u002Fmicroliter (dosage less than 6 months old),\n* Hemostasis disorders, including hemophilia (with thrombocytopenia)\n* Any constitutional or acquired hemorrhagic disease, (including digestive hemorrhages, history of hemorrhagic stroke and thrombocytopenia\n* Human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus positive serum,\n* Patient included in another interventional study which could interfere with the results of the study,\n* Age \\\u003C18 years old,\n* Women under the protection of justice,\n* Patients with psychiatric follow-up, poor understanding of French or cognitive problems,\n* Duodenal ulcer,\n* Severe renal impairment,\n* Severe hepatic insufficiency,\n* Severe cardiac impairment,\n* Gout,\n* Patients with known glucose-6-phosphate dehydrogenase deficiency,","FEMALE","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A randomized clinical trial to assess the efficiency of acetylsalicylic acid (aspirin) 150 mg\u002Fday started before 20 weeks of gestation in the prevention on maternal and fœtal complications in pregnant women with chronic hypertension.",[27,28,29,30,31,32],"Chronic Hypertension Complicating Pregnancy","Pre-Eclampsia","Intrauterine Growth Restriction","Aspirin","Perinatal Death","Placental Abruption","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":37},"2021-02-15",{"date":41,"type":21},"2030-02",{"name":43,"class":44},"Centre Hospitalier Intercommunal Creteil","OTHER",20,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":72,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100642101","phase-4-study-of-aspirin-removal-in-patients-supported-by-the-fully-magnetically-levitated-ch-vad-pump-100642101","NCT07644247","STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump (STAR Trial)","STAR","Inclusion Criteria:\n\n\\-\n\nStudy participants must meet all the following criteria:\n\n1. Age ≥18 years old;\n2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device;\n3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n\\-\n\nStudy participants meet any of the following criteria will be excluded:\n\n1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation;\n2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent;\n3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation);\n4. Inability to take oral medications post-implant through 7 days;\n5. Known allergy to aspirin;\n6. Participation in another clinical investigation that may affect study outcome;\n7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.","ALL",{"count":56,"type":21},370,[58],"PHASE4","This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.",[61,62,63,64,65,66,67,68,69,30,70,71],"LVAD (Left Ventricular Assist Device) Thrombosis","LVAD","LVAD (Left Ventricular Assist Device)","LVAD-related GI Bleed","Bleeding","Thrombosis","Stroke","Hemocompatibility-related Adverse Event","Ventricular Assist Device","Antiplatelet Therapy","Antithrombotic Therapy",[73,62,67,65,66,74,30,75],"Left ventricular assist device","Hemocompatibility","Antiplatelet","NOT_YET_RECRUITING","2026-06-08",{"date":36,"type":37},{"date":80,"type":21},"2026-06-25",{"date":82,"type":21},"2029-12-31",{"name":84,"class":85},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100557242","single-vs-dual-antiplatelet-therapy-in-elderly-or-hbr-patients-undergoing-percutaneous-intervention-with-dcb-piccoleto-iv-epic-38-100557242","NCT06535568","Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","International, Multicenter, Investigator-driven Randomized Clinical Trial to Assess the Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (PICCOLETO IV-EPIC 38)","PIV-EPIC","Inclusion Criteria:\n\nMale and female patients who meet the following criteria:\n\n* Age ≥ 75 years or age ≥ 18 years at high bleeding risk;\n* Successful PCI with Essential Pro DCB just performed, in 1, 2 or 3 coronary vessels;\n* Stable or unstable coronary syndromes;\n* De novo coronary lesions in vessels with diameter ≥2.0 and ≤4.0 mm (visual estimation);\n* Informed consent to participate in the study given by the patient or impartial witness.\n\nExclusion Criteria:\n\n* Stent implantation during index or recent (\\\u003C6 months) procedure;\n* Known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, paclitaxel or contrast media, or any of their excipient which cannot be adequately pre-medicated;\n* Pregnancy at the time of hospitalization;\n* Patients participating in another clinical study in which an investigational drug or device was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer;\n* ST-elevation myocardial infarction;\n* Life expectancy \\\u003C12 months;\n* Left ventricular ejection fraction \\\u003C30%;\n* Visible thrombus at lesion site;\n* Target lesion\u002Fvessel with any of the following characteristics:\n\n  * severe and\u002For \\>270° calcification of the target vessel, also proximal to the lesion (intravascular imaging not mandatory);\n  * left main stem stenosis \\>50%;\n  * target lesion is in the left main stem;\n  * chronic total occlusion with anticipated necessity of retrograde approach;\n  * lesion is in a bypass graft.\n* History of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines (NSAIDs);\n* History of gastrointestinal perforation, ulceration, or bleeding (peptic ulcer bleeding-PUBs) related to previous use of NSAIDs or anticoagulant medications, or intracranial hemorrhage;\n* Acute gastrointestinal ulcers;\n* Hemorrhagic diathesis (including known bleeding disorders or ongoing active bleeding);\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin);\n* Severe hepatic impairment (Child-Pugh C), with elevated liver enzymes (ALT\u002FAST \\> 2 x ULN or total bilirubin \\>1.5 x ULN);\n* Severe cardiac failure (NYHA grade III or IV);\n* Combination with methotrexate at doses of 15 mg\u002Fweek or more;\n* Patients with baseline neutrophil counts \\\u003C 1500 cells\u002Fmm³;\n* Breastfeeding women;\n* Full-blown thyrotoxicosis;\n* Patients with a very high risk of thrombosis.",{"count":95,"type":21},576,[97],"NA","This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients undergoing percutaneous coronary intervention (PCI) with the latest generation drug-coated balloon (DCB). The study includes patients with stable or unstable coronary syndromes and aims to assess rates of ischemic and bleeding adverse events.",[100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,30,123],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Myocardial Ischemia","Atherosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Coronary Artery Disease","Acute Coronary Syndrome","Coronary Stenosis","Molecular Mechanisms of Pharmacological Action","Enzyme Inhibitors","MTOR Inhibitors","Protein Kinase Inhibitors","Physiological Effects of Drugs","Immunosuppressive Agents","Antineoplastic Agents","High Bleeding Risk","Single Antiplatelet Therapy","Dual Antiplatelet Therapy","Cyclooxygenase Inhibitors","P2Y12 Inhibitor","Platelet Aggregation Inhibitors","Clopidogrel",[125,126,127,128,129,130,131,132,133,134],"DCB","Angioplasty","Paclitaxel","Antiplatelet treatment","Single antiplatelet therapy (SAPT)","Dual antiplatelet therapy (DAPT)","High bleeding risk (HBR)","MACE","Native CAD","stable or unstable coronary syndromes","2026-01-21",{"date":137,"type":37},"2026-01-22",{"date":139,"type":37},"2026-01-10",{"date":141,"type":21},"2028-02-20",{"name":143,"class":44},"Fondazione Ricerca e Innovazione Cardiovascolare ETS",1,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":156,"conditions":157,"keywords":161,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":144},"100493231","phase-1-assessing-pharmacokinetics-and-pharmacodynamics-of-daily-enteric-coated-aspirin-in-patients-with-stable-diabetes-ii-100493231","NCT05702463","Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II","APPEASEDII","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Participant must be naïve to ASA, defined as absence of chronic treatment with ASA within the previous 3 months, and of any ASA use within the previous 2 weeks;\n3. Type 2 diabetes, based on at least one of the following criteria: (5)\n\n   * Chronic treatment with oral antihyperglycemic agents or insulin therapy;\n   * Fasting Plasma Glucose (FPG) ≥ 126 mg\u002FdL (7.0 mmol\u002FL) (fasting is defined as no caloric intake for at least 8h);\n   * 2-h Plasma Glucose (2h-PG) ≥ 200 mg\u002FdL (11.1 mmol\u002FL) during the oral glucose tolerance test (OGTT);\n   * A1C ≥ 6.5% (48 mmol\u002Fml);\n4. Willing to attend all study visits of both the run-in and randomized phases of the trial.\n\nExclusion Criteria:\n\n1. Definitive indication for ASA, including any evidence of clinical atherosclerotic disease, previous or current;\n2. Known hypersensitivity to ASA;\n3. Patient requiring dialysis;\n4. Severe hepatic insufficiency or ALT \\> 3 x ULN;\n5. High-risk GI bleeding features, such as known H. pylori infection, past or present ulcer, history of bleeding from the GI tract;\n6. Bleeding diathesis;\n7. Platelet count or hemoglobin levels outside of the normal reference range;\n8. Planned major surgical procedure or dental procedure during the course of the study;\n9. Chronic inflammatory disease requiring regular anti-inflammatory treatment;\n10. Chronic treatment with an oral anticoagulant, an antiplatelet agent, NSAIDs or systemic steroids;\n11. Active cancer;\n12. History of hematological malignancy or myelodysplasia;\n13. Pregnant or lactating women;",{"count":153,"type":21},30,[155],"PHASE1","This phase 2 study will include patients suffering from type 2 diabetes mellitus and will first study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period. Participants with an incomplete platelet inhibition after exposure to EC aspirin at doses of 80 mg once daily will be randomized to a random order of 3 different ASA regimens: EC ASA 162 mg once daily, EC ASA 81 mg twice daily and chewable ASA 40 mg twice daily. The aims are to determine the feasibility of a larger scale trial, and to determine the regimen associated with the lowest proportion of non-responders after randomization. Platelet function will be assessed at baseline and at day 7 of each arms of the study.",[158,159,30,160,122],"Platelet Aggregation","Type 2 Diabetes","Diabetes Mellitus, Type 2",[162,163,164,165],"diabetes","aspirin","Acetylsalicylic acid","Pharmacodynamics","2025-12-02",{"date":168,"type":37},"2025-12-03",{"date":170,"type":37},"2023-06-13",{"date":172,"type":21},"2027-07-01",{"name":174,"class":44},"Montreal Heart Institute",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":189,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100602584","phase-4-non-antithrombotic-versus-single-antiplatelet-therapy-following-left-atrial-appendage-closure-100602584","NCT07125417","Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure","Non-Antithrombotic Versus. Single antiPlatelet Therapy Following Left Atrial Appendage Closure：NAPT-LAAC Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patient has documented non-valvular atrial fibrillation (i.e, atrial fibrillation without severe mitral stenosis or mechanical valves)\n2. Patient has CHA2DS2-VA score of 2 or greater\n3. Patient meets the guidelines for proper use of the left atrial appendage closure system including patient who has an increased risk of bleeding.\n4. Individual with nonvalvular atrial fibrillation who underwent successful LAAC (defined as no significant residual circumferential leak \\[\\>3 mm\\] or major morbidity by the time of procedure completion).\n5. Patient suitable for pharmacotherapy as defined in this study protocol in both NAPT and SAPT arms\n6. LAA anatomy is accommodate Boston Scientific WATCHMAN FLX Pro and LAAC procedure\n7. The patient and the investigator and\u002For subinvestigator agree that the patient will return for all required VISITs after LAAC procedure\n8. Patient has thoroughly understood the purpose of the study and has provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Patients who are currently enrolled in other clinical trials, except when the patient is participating in a mandatory governmental registries or purely observational registries with no associated treatment.\n2. Individuals require long-term anticoagulation therapy for reasons other than atrial fibrillation (AF)-related stroke risk reduction (e.g.,thrombophilic conditions, previous pulmonary embolism, or deep venous thrombosis).\n3. Patients requiring oral antiplatelet therapy for reasons other than LAAC (e.g.,history of myocardial infarction, history of endovascular treatment, history of stroke\u002Ftransient ischemic attack, significant coronary stenosis proven by myocardial ischemia, severe carotid stenosis requiring invasive treatment,hematologic disease such as antiphospholipid syndrome or if the investigator and\u002For subinvestigator judged the need for antiplatelet therapy).\n4. Patients who meet one or more of the following criteria\n\n   * Patients who are contraindicated for DOAC or VKA\n   * Patients with a contraindication to aspirin\n   * Patients diagnosed with an allergy to aspirin\n5. Those who have or are scheduled to undergo cardiac or noncardiac intervention or surgery 45 days or 60 days before or after LAAC (e.g.,cardioversion, PCI, cardiac ablation, cataract surgery, other structural heart interventions).\n6. Patients with stroke (either ischemic or hemorrhagic) or transient ischemic attack within 30 days prior to enrollment\n7. Patients with active bleeding\n8. Individuals who lack LAA or whose LAA has been surgically ligated\n9. Individuals who experienced a myocardial infarction (with or without intervention) recorded as a non-ST elevation myocardial infarction or ST elevation myocardial infarction in the 30-day period prior to enrollment\n10. Patients with previous atrial septal repair or with atrial septal defect\u002Fpatent foramen ovale device\n11. Patients with mechanical valve prostheses at any site\n12. Persons with known contraindications to TEE\n13. Patients with active infection\n14. Individuals with NYHA class related IV congestive heart failure at enrollment\n15. Patients who are pregnant, breastfeeding, or wishing to become pregnant\n16. Patients with an expected life expectancy of less than 2 years\n17. Patients requiring emergency surgery for any reason\n18. Patients who, at the discretion of the investigator, have other medical, social, or psychological conditions that preclude adherence to appropriate consent or the follow-up tests required by the protocol\n19. Other patients whose investigator or subinvestigator judges their participation in the study to be inappropriate",{"count":20,"type":21},[58],"The goal of this clinical trial is to verify that Non-Antithrombotic Therapy (NAPT) followed by Oral Anticoagulants (OAC) monotherapy for 45 days after Left Atrial Appendage Closure (LAAC) is non-inferior to Single Antiplatelet Therapy (SAPT) with aspirin during the period from randomization to the end of observational period (4 years at the maximum) in non-valvular atrial fibrillation subjects with high bleeding risk.\n\nThe primary endpoint is a composite endpoint consisting of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, or clinically relevant non-fatal bleeding from randomization to the end of study observation (up to a maximum follow-up of 4 years).\n\n* Participants will be enrolled in this study until the day following the implementation of LAAC and will be randomized to the SAPT arm and NAPT arm in a 1:1 ratio.\n* Participants will be observed for 4 years from the time the first subject is enrolled in this study.\n* Participants will visit the hospital at 45 days, 1 year, and 2 years after enrollment, and will also be followed up by telephone, basically at the end of the observation period (up to a maximum follow-up of 4 years).\n\n\\\u003CStudy treatment duration\\> In both arms, OAC monotherapy will be initiated in the first 24 hours of enrollment and continued for 45 days (allowed window period: plus 2 weeks)..\n\n* SAPT arm will continue to receive 45 days of OAC monotherapy followed by low-dose aspirin (75～100 mg\u002Fday) as an antithrombotic agent required through the end of the study observation period.\n* NAPT arm do not receive antithrombotic medication after 45 days of OAC monotherapy through the end of the study observation period.",[186,30,187,117,188],"Nonvalvular Atrial Fibrillation","Non-Antithrombotic Therapy","Left Atrial Appendage Closure",[188,190,191,30,192],"High bleeding risk","Non-Antithrombotic therapy","Nonvalvular Artial Fibrillation","2025-08-12",{"date":195,"type":37},"2025-08-15",{"date":197,"type":37},"2025-05-29",{"date":199,"type":21},"2030-03-31",{"name":201,"class":44},"OCEAN-SHD Study Group",21,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":210,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":212,"studyType":213,"phases":4,"briefSummary":214,"conditions":215,"keywords":218,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":144},"100583939","immunomodulation-during-pregnancy-100583939","NCT06882850","Immunomodulation During Pregnancy","Immunomodulation During Pregnancy Through Low-Dose Aspirin: a Hypothetical Mechanism for the Prevention of Preeclampsia?","Inclusion Criteria: - Singleton pregnancy\n\n* Patients attending prenatal consultations at the Obstetrics Service A of CHUC, with the first consultation occurring before 14 weeks of gestation\n* Gestational age determined by first-trimester ultrasound\n* Study group: Women classified as high risk for PE according to clinical\u002Fhistorical criteria and the Fetal Medicine Foundation algorithm. LDA-naïve.\n\nExclusion Criteria: Multiple pregnancy\n\n* Autoimmune diseases\n* Prior use of LDA or other immunomodulatory medication before potential recruitment\n* History of spontaneous miscarriages and\u002For medical termination of pregnancy\n* Fetal malformation",true,{"count":153,"type":21},"30 Weeks","OBSERVATIONAL","The goal of this observational study is to learn about the effects of low dose aspirin in immunity Pregnant women taking aspirin for other reasons (preeclampsia prevention) will be studied. The main question it aims to answer is: evaluate the effect of LDA on the modulation of innate immunity cells (NK cells, monocytes, γδ T cells) and\u002For acquired immunity (B and T lymphocytes, Treg cells, Th cells).\n\nParticipants already taking intervention A as part of their regular medical care for RA will answer online survey questions about their joint pain for 5 years.",[30,216,217],"Pregnancy Complications","Immunology",[217,219,30,220,221],"Pregnancy","Lymphocytes","T-Lymphocytes","2025-03-15",{"date":224,"type":37},"2025-03-19",{"date":226,"type":37},"2024-02-01",{"date":228,"type":21},"2025-03-31",{"name":230,"class":44},"Unidade Local de Saúde de Coimbra, EPE",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":246,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":266},"100554114","phase-3-the-partum-trial-postpartum-aspirin-to-reduce-thromboembolism-undue-morbidity-100554114","NCT06494878","The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity","The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial","Inclusion Criteria:\n\n* ONE (or more) First Order Criterion:\n\n  1. Known inherited thrombophilia diagnosed prior to enrolment, regardless of family history of VTE:\n\n     i. Heterozygous factor V Leiden, or ii. Heterozygous prothrombin gene variant, or iii. Protein C deficiency, or iv. Protein S deficiency, and\u002For\n  2. Antepartum immobilization for ≥7 days. Immobilization is defined as bed rest with 90% of waking hours spent in bed at any time during the antepartum period AND\u002FOR\n\nTWO (or more) Second Order Criteria:\n\n1. Pre-pregnancy BMI ≥30 kg\u002Fm²\n2. Smoking in the current pregnancy or within 3 months prior to pregnancy\n3. Previous clinical history of superficial vein thrombosis\n4. Preeclampsia\n5. Current pregnancy ending in stillbirth (pregnancy loss \\>20 weeks gestation)\n6. Unplanned cesarean delivery (unplanned = not a scheduled cesarean delivery)\n7. Small-for-gestational-age infant at time of delivery (\\\u003C3rd percentile adjusted for gestational age and sex)\n8. Peripartum or postpartum infection (symptoms\u002Fsigns of infection and documented fever and laboratory evidence of infection with positive blood cultures or an elevated white blood cell count based on local laboratory cutoffs)\n9. Postpartum hemorrhage (≥1000 mL of blood loss, regardless of delivery mode)\n\nExclusion Criteria:\n\n1. More than 48 hours since delivery at the time of randomization\n2. Received more than 1 dose of LMWH since delivery\n3. Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by their physician and\u002For local investigator. May include but is not limited to:\n\n   1. Documented history of provoked or unprovoked VTE\n   2. Mechanical heart valve(s)\n   3. Known antiphospholipid syndrome (APS)\n   4. Known high-risk inherited thrombophilia i) Antithrombin deficiency, or ii) Homozygous factor V Leiden, or iii) Homozygous prothrombin gene mutation, or iv) More than 1 thrombophilia: any combination of 2 or more: factor V Leiden, prothrombin gene mutation, protein C deficiency, protein S deficiency\n4. Need for postpartum ASA as judged by their physician and\u002For local investigator. May include but is not limited to:\n\n   1. Documented history of myocardial infarction\n   2. Documented history of ischemic stroke or transient ischemic attack (TIA)\n5. Active bleeding, excluding normal vaginal bleeding, at the time of randomization\n6. Known medical condition as judged by their physician and\u002For local investigator to be a contraindication to ASA or LMWH including known ASA or LMWH allergy\n7. \\\u003C18 years of age\n8. Unable or declined consent",{"count":239,"type":21},8805,[24],"The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.",[243,244,30,245],"Venous Thromboembolism","Postpartum Period","Low Molecular Weight Heparin",[247,248,249,250,251,252,253,254,255,256],"deep vein thrombosis","pulmonary embolism","postpartum","pregnancy","thrombophilia","cesarean delivery","preeclampsia","small-for-gestational age infant","postpartum hemorrhage","postpartum infection","2025-02-26",{"date":259,"type":37},"2025-03-03",{"date":261,"type":21},"2025-04",{"date":263,"type":21},"2030-12",{"name":265,"class":44},"University of Calgary",3,{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":54,"minAge":275,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":5},"100379010","phase-3-aspirin-use-for-gastric-cancer-prevention-in-the-early-gastric-cancer-patients-100379010","NCT04214990","Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients","Effect of Low-dose Aspirin for Stomach Cancer Prevention After Endoscopic Resection of Gastric Neoplasm (EASTERN): a Randomized Controlled Trial","EASTERN","Inclusion Criteria:\n\n* Men and women aged 19-70 years who underwent endoscopic resection for high-grade adenoma or early gastric cancer (category 4 \\[non-invasive high grade neoplasm\\] or category 5 \\[invasive neoplasia\\] according to the Vienna classification of gastrointestinal epithelial neoplasia \\[Schlemper RJ, et al. Gut 2000;47:251-255.\\])\n* Final pathological results after endoscopic resection met the absolute or expanded criteria according to the Japanese Gastric Cancer Treatment guideline 2014 (version 4)\n* Patients who had negative H. pylori status or those who eradicated H. pylori status\n* Willingness to sign an informed consent form\n\nExclusion Criteria:\n\n* Patients who received aspirin for the secondary prevention of cardiovascular diseases or cerebrovascular diseases\n* Regular aspirin uses (more than 3 times a week) with 2 months before screening visit\n* Patients who used anticoagulants or antiplatelet drugs for therapeutic purpose\n* Previous gastrectomy history\n* Current treatment for serious medical condition which could hinder participation (such as severe heart dysfunction, liver cirrhosis, renal failure, COPD or bronchial asthma, or uncontrolled infection)\n* High risk patients for bleeding complications (cerebral aneurysm, vascular malformation, esophageal or gastric varices, or hemophilia, etc)\n* Active peptic ulcer disease (patients who treated peptic ulcer completely could be enrolled)\n* Diagnosis and active treatment for other organ cancer (except carcinoma in situ, and non-melanoma skin cancer) within 5 years\n* Non-curative resection of early gastric cancer after endoscopic resection\n* Aspirin allergy or contraindication of aspirin use\n* Pregnant or lactating women\n* Alcoholism, drug abuse\n* Inadequate patients for study enrollment according to the evaluation of the study physician\n* Inability to provide an informed consent\n* Patients who took a 28-day run-in-period medication less than 80%","19 Years","70 Years",{"count":278,"type":21},1700,[24],"This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.",[30,282],"Gastric Cancer",[30,284,285],"Gastric cancer prevention","Endoscopic submucosal dissection","2024-12-25",{"date":288,"type":37},"2024-12-27",{"date":290,"type":37},"2020-02-15",{"date":292,"type":21},"2032-03-31",{"name":294,"class":85},"National Cancer Center, Korea",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":54,"minAge":301,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":144},"100516645","phase-4-non-antithrombotic-therapy-after-transcatheter-aortic-valve-implantation-trial-100516645","NCT06007222","Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial","Inclusion Criteria:\n\n1. Patients who underwent transfemoral TAVI for aortic stenosis\n2. Patients aged 20 years or older at the time of informed consent\n3. Patients who have a thorough understanding of the subject of the study and who have agreed in writing to participate in the study\n\nExclusion Criteria:\n\n1. Those with perioperative complications at the time of TAVI (conversion to open heart surgery, coronary artery occlusion, annulus rupture, cardiac tamponade, vascular dissection, cerebral infarction\u002Fcerebral hemorrhage, new atrial fibrillation, new atrioventricular block)\n2. Individuals requiring antiplatelet agents for reasons other than TAVI (history of myocardial infraction, history of PCI（Percutaneous Coronary Intervention）, history of EVT（EndoVascular Treatment）, history of cerebral infraction and transient ischaemic stroke, with significant coronary artery narrowing, with high-grade carotid artery narrowing, and others judged as requiring antiplatelet therapy by the chief researcher or a sub-investigator)\n3. Patients requiring oral anticoagulants (patients with atrial fibrillation, history of pulmonary embolism or deep venous thrombosis, and other patients who are deemed to require anticoagulation therapy by the investigator or coinvestigator)\n4. Patients with eGFR（estimated Glomerular Filtration Rate） \\\u003C30 and patients on hemodialysis\u002Fperitoneal dialysis.\n5. Patients with a history of valve replacement in the heart valves.\n6. Patients who are pregnant, have childbearing potential, wish to become pregnant, or are breastfeeding.\n7. Patients who have a concomitant medical illness associated with expected survival less than one year.\n8. Patients who have the contraindications for aspirin.\n9. Patients with a diagnosis of severe allergy to aspirin or a history of hypersensitivity.\n10. Patients requiring a legally acceptable representative, patients unable to obtain written informed consent, or patients unable to understand the outline or purpose of the study.\n11. Other patients for whom the principal investigator or the coinvestigator judges the participation in the study inappropriate.","20 Years",{"count":303,"type":21},400,[58],"Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg\u002Fday the end of the study period.\n\nNon-antithrombotic group: No antithrombotic agents will be administered after randomization until the end of the study period.",[307,308,30,309,310],"Aortic Stenosis","TAVI(Transcatheter Aortic Valve Implantation)","DAPT(Dual Antiplatelet Therapy)","SAPT(Single Antiplatelet Therapy)","2024-09-20",{"date":313,"type":37},"2024-09-23",{"date":315,"type":37},"2023-04-06",{"date":317,"type":21},"2027-12-31",{"name":201,"class":44},{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":54,"minAge":326,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":144},"100530349","the-effect-of-aspirin-on-recurrent-acute-pancreatitis-100530349","NCT06185621","The Effect of Aspirin on Recurrent Acute Pancreatitis","The Effect of 100mg Aspirin on Recurrent Acute Pancreatitis: a Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with with recurrent acute pancreatitis\n\nExclusion Criteria:\n\n* Less than 2 episodes of acute pancreatitis in the past year\n* Latrogenic AP (pancreatitis due to endoscopic retrograde cholangiopancreatography, surgery, or after other invasive treatment). Iatrogenic pancreatitis will not count as an episode of recurrent pancreatitis\n* Previous allergy to Non-Steroid Anti-inflammatory Drugs (NSAIDs)\n* Regularly taking aspirin or other NSAIDs \\>3 doses per week\n* Contradictions for the medications of NSAIDs, including Active peptic ulcer disease or gastrointestinal hemorrhage within 3 months or previous peptic ulcer, history of significant hepatic or renal disease, platelet count less than 100X10\\^9\u002FL or international normalized ratio (INR) \\>1.5)\n* Biliary stones\n* Receiving endoscopic sphincterotomy and\u002For pancreatic stent placement and\u002For cholecystectomy and\u002For pancreatic surgery after the latest pancreatitis or planning to undergo one of those interventions within preceding 2 years\n* Patients with the level of serum triglycerides of \\>5.65 mmol\u002FL and did not receive regular lipid-lowering therapy\n* Primary hyperparathyroidism has been well-treated after last episode of pancreatitis and recruitment or will be operated in \\\u003C2 years\n* Patients with previously heavy alcohol consumption (50g\u002Fday for men, 40g\u002Fday for women) and have not quit drinking, or have significant withdrawal symptoms\n* Pregnant or breastfeeding patients\n* Inability to give informed consents","14 Years","80 Years",{"count":329,"type":21},23,[97],"Recurrent acute pancreatitis (RAP) was defined as two or more occurrences of acute pancreatitis, which was associated with higher percentages of morbidities and mortalities, lower patients' life quality and increased health-care costs. Current interventions, including cholecystectomy and abstain from drinking were reported to be effective methods for preventing the recurrences of biliary and alcoholic etiologies, respectively. However, there were no effective preventions for other etiologies, such as idiopathic etiologies. Non-steroid anti-inflammatory drugs (NSAIDs), including indomethacin, diclofenac and aspirin could inhibiting the inflammatory cascade of pancreatitis. In this study, we aimed at exploring the effects of 100mg aspirin on reducing the occurrences of recurrent acute pancreatitis.",[333,334,30],"Recurrent Acute Pancreatitis","Prevention","2023-12-15",{"date":337,"type":37},"2023-12-29",{"date":339,"type":37},"2023-11-01",{"date":341,"type":21},"2026-11-01",{"name":343,"class":44},"Air Force Military Medical University, China"]